www.nature.com/scientificreports
OPEN
Received: 10 January 2019
Accepted: 15 July 2019
Published: xx xx xxxx
The TM6SF2 E167K genetic variant
induces lipid biosynthesis and
reduces apolipoprotein B secretion
in human hepatic 3D spheroids
Sebastian Prill1, Andrea Caddeo2, Guido Baselli3, Oveis Jamialahmadi2, Paola Dongiovanni3,
Raffaela Rametta3, Kajsa P. Kanebratt1, Arturo Pujia4, Piero Pingitore2,
Rosellina Margherita Mancina 2, Daniel Lindén5,6, Carl Whatling7, Annika Janefeldt 1,
Mikael Kozyra8, Magnus Ingelman-Sundberg 8, Luca Valenti3, Tommy B. Andersson1,8 &
Stefano Romeo 2,4,9
There is a high unmet need for developing treatments for nonalcoholic fatty liver disease (NAFLD), for
which there are no approved drugs today. Here, we used a human in vitro disease model to understand
mechanisms linked to genetic risk variants associated with NAFLD. The model is based on 3D spheroids
from primary human hepatocytes from five different donors. Across these donors, we observed highly
reproducible differences in the extent of steatosis induction, demonstrating that inter-donor variability
is reflected in the in vitro model. Importantly, our data indicates that the genetic variant TM6SF2
E167K, previously associated with increased risk for NAFLD, induces increased hepatocyte fat content
by reducing APOB particle secretion. Finally, differences in gene expression pathways involved in
cholesterol, fatty acid and glucose metabolism between wild type and TM6SF2 E167K mutation carriers
(N = 125) were confirmed in the in vitro model. Our data suggest that the 3D in vitro spheroids can be
used to investigate the mechanisms underlying the association of human genetic variants associated
with NAFLD. This model may also be suitable to discover new treatments against NAFLD.
Nonalcoholic fatty liver disease (NAFLD) is considered a global epidemic1 and the most common cause of
chronic liver disease worldwide, with increasing prevalence2,3. It comprises a range of conditions, from relatively benign simple steatosis to more progressed forms, including nonalcoholic steatohepatitis (NASH) and
liver fibrosis which may progress to cirrhosis and hepatocellular carcinoma4–6 as well as cardiovascular morbidities7,8. NAFLD has a strong genetic component9, with the patatin-like phospholipase domain containing 3 I148M
(rs738409, PNPLA3 I148M) and transmembrane 6 superfamily member 2 E167K (rs58542926, TM6SF2 E167K)
genetic variants having the largest effect on the susceptibility to the entire spectrum of liver disease9.
Accumulation of intrahepatic fat is the hallmark of NAFLD. Despite a Mendelian Randomization study10
suggesting a causal role of fat accumulation in causing liver fibrosis, the mechanism behind the toxicity of intracellular neutral lipid is not clear. The increase in hepatocyte intracellular fat can be attributed to derangements of
at least four main metabolic pathways: increased triglyceride (TG) synthesis, increased TG uptake, decreased fat
1
DMPK, Cardiovascular, Renal and Metabolism, IMED Biotech Unit, AstraZeneca, Gothenburg, Sweden. 2Department
of Molecular and Clinical Medicine, University of Gothenburg, Gothenburg, Sweden. 3Internal Medicine and Metabolic
Diseases, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico Milano, Department of Pathophysiology
and Transplantation, Università degli Studi di Milano, Milan, Italy. 4Clinical Nutrition Unit, Department of Medical
and Surgical Sciences, University Magna Graecia, Catanzaro, Italy. 5Bioscience Diabetes, Cardiovascular, Renal and
Metabolism, IMED Biotech Unit, AstraZeneca, Gothenburg, Sweden. 6Division of Endocrinology, Department of
Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden. 7Translational
Sciences, Cardiovascular, Renal and Metabolism, IMED Biotech Unit, AstraZeneca, Gothenburg, Sweden.
8
Department of Physiology and Pharmacology, Section of Pharmacogenetics, Karolinska Institutet, Stockholm,
Sweden. 9Cardiology Department, Sahlgrenska University Hospital, Gothenburg, Sweden. Correspondence and
requests for materials should be addressed to S.R. (email: stefano.romeo@wlab.gu.se)
SCIENTIFIC REPORTS |
(2019) 9:11585 | https://doi.org/10.1038/s41598-019-47737-w
1
www.nature.com/scientificreports/
www.nature.com/scientificreports
secretion or decreased fatty acid (FA) oxidation11. In genetic association studies carriers of the TM6SF2 E167K
variant have substantially higher risk of NAFLD and at the same time lower risk for cardiovascular disease12–14.
Human TM6SF2 E167K carriers have lower circulating apolipoprotein B100 (APOB) levels12,15 suggesting a
reduction in the number of secreted lipoproteins. The TM6SF2 E167K genetic variant may result in a misfolded
protein that is prone to intracellular degradation resulting in reduced protein levels13,16. Tm6sf2 inactivation in
mice is, like in humans, associated with hypocholesterolemia and increased liver fat accumulation. In addition,
hepatic VLDL-TG secretion rate is reduced while the APOB secretion is unaffected in the Tm6sf2 knock-out (KO)
mice, indicating no change in the number of secreted lipoprotein particles from the liver17 in discordance with
the human data12,15.
At present, there is no effective and approved pharmacotherapy available for the treatment of NAFLD. For
development efforts aiming at novel treatments, disease models reflecting human NAFLD are required. Numerous
dietary and genetic animal models are used for investigating the disease and its progression, of which most are
rodent models18,19. The indisputable advantage of in vivo models is the representation of the (patho)physiological interplay of organs in the body. However, animal models have also clear limitations such as interspecies
differences across liver pathways20,21, disease characteristics21,22, high costs and ethical concerns. Thus, human in
vitro systems are commonly used to complement animal experimentation23. To address the limitations of simple
human in vitro models culturing primary hepatocytes in a classical 2D monolayer, 3D spheroids generated from
primary human hepatocytes have proven to be excellent surrogates for human physiology24 by providing an in
vivo-like cellular microenvironment24,25. However, spheroids composed of primary human hepatocytes have not
been exploited as a model to investigate molecular genetic mechanisms involved in the development of NAFLD.
Aim of this work was to generate a 3D spheroid model to study molecular genetics of NAFLD. To achieve
this goal we first examined differences in hepatic lipid metabolism between wild type (WT) and carriers of the
TM6SF2 E167K genetic variant using human data from hepatic transcriptome. Next, we used a recent in vitro 3D
spheroid NAFLD model from primary human hepatocytes26. This in vitro system reflects the liver physiology of
WT and TM6SF2 E167K donors.
Results
Enrichment analyses between TM6SF2 wild type and TM6SF2 E167K (rs58542926) mutant carriers. We examined liver-derived RNA-Seq data from 125 patients at risk for NAFLD diagnosed by liver biopsies
(Supplementary Tables S1 and S2). Among these, 116 were wild type (WT) and 9 were E167K mutant carriers. Since
DESeq2 analysis did not show any differentially expressed gene, we hypothesized that the insignificant adjusted
p-values are the direct consequence of low number of heterozygous carriers of the TM6SF2 E167K mutation (N = 9)
compared to WT (N = 116). Therefore, to understand the metabolic changes in TM6SF2 E167K carriers, we performed enrichment for genes with a nominal p-value < 0.05 which are related to hepatic glucose and lipid metabolism using Gene Ontology (GO) biological process (BP) terms and KEGG biological pathways (Supplementary
Table S4). The most enriched GO terms and KEGG pathways were those related to cholesterol (cholesterol GO:0006695 and sterol biosynthetic - GO:0016126 processes in GO-BP, and terpenoid backbone biosynthesis in
KEGG), TG (GO:0006641) and FA metabolism (GO:0019217). Interestingly, KEGG pathways associated with viral
hepatitis (Hepatitis C and B) and NAFLD were significantly enriched in our list of examined genes.
Spheroid morphology. Next, we generated a 3D spheroid model from primary human hepatocytes obtained
from five individual donors, of which two were heterozygous for the TM6SF2 E167K allele, and three were WT. To
avoid confounders, we refrained from using primary human hepatocytes carrying the PNPLA3 rs738409 variant
(encoding for an isoleucine to methionine substitution at position 148 of the PNPLA3 protein, I148M), the strongest common genetic variant increasing liver fat content27. Furthermore, donors were genotyped for the PNPLA3
rs2294918 (E434K), GCKR rs1260326 (P446L) and MBOAT7 rs641738 (C > T) NAFLD risk alleles (Supplementary
Table S5). A total of 2,000 cryopreserved primary human hepatocytes from each of the five donors were seeded
per well at day −7 (Fig. 1A). After one day cells started to aggregate, forming a 3D structure (Fig. 1B). After three
days of culture the aggregates resulted in spheroidal structures (Fig. 1C), further condensing over the following 4
days (Fig. 1D,E). During the spheroid formation the diameter of the entirety of seeded cells from the WT-1 donor
decreased by approximately 45%, starting from a diameter of 450 µm (Supplementary Fig. S1). This formation pattern was similar in all donors. At day 0 the spheroids were fully formed with intact and distinct borders (Fig. 1E).
Spheroids are viable and well differentiated up to 10 days with and without fatty acid incubation. To generate a 3D spheroid hepatocyte model of NAFLD, we incubated spheroids with increasing
amounts of 2:1 oleic:palmitic acid-enriched medium (160 µM, 240 µM (data not shown) and 320 µM total FA
concentration, conjugated to bovine serum albumin (BSA), as described previously26. Medium was changed every
two days with sampling of spheroids and medium supernatant as depicted in Fig. 1. To test whether FA incubation results in spheroid morphological changes we measured the size at treatment days two, four, six and ten. We
found no differences in diameter across days and with different treatment concentrations of FAs (Supplementary
Fig. S2). We also examined shape and spheroid borders, which remained spherical with intact and distinct borders throughout all treatment conditions and time points (Fig. 2, Supplementary Fig. S3).
To assess the viability of cultured spheroids, we determined intracellular ATP content after incubation with
and without FAs using two different concentrations at treatment day two, four, six and ten (Fig. 3). We observed
no differences in the ATP concentration among groups throughout treatment concentrations and time points.
Next, we evaluated differentiation of hepatocytes in spheroids by determining intracellular and extracellular levels of APOB, a protein only expressed in hepatocytes and involved in hepatocyte TG secretion by very
low-density lipoprotein (VLDL), a pathway present exclusively in hepatocytes. We found that APOB protein
SCIENTIFIC REPORTS |
(2019) 9:11585 | https://doi.org/10.1038/s41598-019-47737-w
2
www.nature.com/scientificreports/
www.nature.com/scientificreports
Figure 1. Overview of spheroid generation and study design. Spheroids were generated by incubating 2000
primary human hepatocytes for 7 days in 384- or 96-well ultra-low attachment plates. Initiation of spontaneous
cell aggregation was observed within one day after seeding. Hepatocytes from five individual donors were used
in two independent experiments for WT-1, WT-2 and TM6SF2 E67K-2, and in one independent experiment for
WT-3 and TM6SF2 E167K-1, respectively (data from repeat experiments shown in Supplementary Fig. S7). For
each experiment, an individual vial of cryopreserved primary hepatocytes was used for spheroid preparation.
Bright-field images representatively show spheroid formation by spontaneous aggregation of hepatocytes
obtained from donor WT-1. Hepatocytes from all other donors showed similar spheroid formation behavior,
yielding fully formed spheroids after 7 days. Arrows in the timeline depict medium changes for incubation with
FA and samplings for bright field (Figs 2A–C and S3) and confocal (Figs 5B and S4) imaging, intracellular ATP
content (Fig. 3), intracellular and secreted APOB (Figs 4 and 7A,B), intracellular total TG content (Fig. 5A)
and gene expression profiling (Figs 6 and 7C), respectively. Bars = 200 µm. Abbreviations: ATP, adenosine
triphosphate; APOB, APOLIPOPROTEINB100; FA, fatty acid; TG, triglyceride, WT, wild type.
synthesis was preserved (Figs 4A and 7A,B) from beginning of treatment up to the end (10 days). Also, the synthesized APOB was consistently secreted into the extracellular space up to the end of the treatment, as shown by
protein levels in the medium (Figs 4B and 7A,B).
All these data suggest that spheroids are viable, well differentiated and functional up to 10 days of incubation
with FAs.
FA incubation results effectively in intracellular neutral lipid accumulation. To test whether FA
incubation results in an increased fat content in the spheroids, we measured total intracellular TG content in
single cell suspension obtained from disintegrated spheroids by fluorescence intensity using AdipoRed assay
reagent (Fig. 5A) and by confocal Nile Red imaging of fixed and morphologically intact spheroids after two, six
(Supplementary Fig. S4) and 10 days (Fig. 5B) of FA incubation. We found an increase in the total amount of
intracellular fat content after incubation with increasing amounts of FAs in all donors (Supplementary Fig. S5,)
and with increasing duration of the incubation (Supplementary Fig. S6). Incubation with an intermediate concentration of FA (240 µM; 160 µM OA/80 µM PA) led to an intermediate treatment response lying between the
ones of low and high FA concentration (data not shown). Overall, the TM6SF2 E167K-1 and -2 donors had higher
intracellular lipids from day four to the end of the incubation.
Importantly, donor-specific patterns in fat accumulation were robustly confirmed during one repeat experiment for donors TM6SF2 E167K-2, WT-1 and WT-2, using low and high FA concentrations (Supplementary
Fig. S7).
™
RNA measurement of key metabolic genes from human genetic analyses. Next, to compare the
in vitro results with our ex vivo data in human liver, we measured the gene expression levels of the enzymes in
the cholesterol, FA metabolism and gluconeogenesis pathway that were significantly differentially expressed in
humans carrying the TM6SF2 mutant protein, both in spheroids carrying the TM6SF2 E167K and WT allele.
We compared the expression levels in TM6SF2 E167K (pooled from 2 donors) and WT (pooled from 3 donors)
spheroids after 2 days of incubation with high FA concentration (320 µM total FA, 213 µM OA/107 µM PA), and
examined the directional regulation (up or down) of these genes (Supplementary Table S3).
Consistent with the human ex vivo data, genes related to cholesterol biosynthesis (FDPS, HMGCS1, FDFT1,
DHCR7 and SC5D), de novo lipogenesis (FASN and ACSS2) and phospholipid dephosphorylation (PLPP3) were
upregulated in the hepatic TM6SF2 E167K spheroids, while gluconeogenesis (FBP1) was upregulated in the spheroids and downregulated in humans carrying the E167K risk variant (Fig. 6). ACADS, an enzyme involved in
FA β-oxidation was upregulated in spheroids, but downregulated in human ex vivo data. PNPLA2, an enzyme
involved in TG metabolism, was upregulated in spheroids, but downregulated in humans (Fig. 6).
SCIENTIFIC REPORTS |
(2019) 9:11585 | https://doi.org/10.1038/s41598-019-47737-w
3
www.nature.com/scientificreports/
www.nature.com/scientificreports
Figure 2. Spheroids show no morphological changes for up to 10 days of FA treatment. Bright-field images of
spheroids from the TM6SF2 E167K-2 (A), WT-1 (B) and WT-2 (C) donor, without (top row, Control, FA-free
BSA) and with FA treatment (bottom row, high FA, BSA + 213 µM OA/107 µM PA) for up to 10 days showed
no morphological differences between the two populations. Corresponding bright-field images of the TM6SF2
E167K-1 and WT-3 donors are shown in Supplementary Fig. S3. Bar = 200 µm. Abbreviations: BSA, bovine
serum albumin; FA, fatty acid; OA, oleic acid; PA, palmitic acid; WT, wild type.
Spheroids carrying the TM6SF2 E167K variant have lower APOB secretion.
To understand the
consequences of carriage of the TM6SF2 E167K variant, we examined the relative difference in APOB levels in
the medium supernatant from spheroids of the donors. Medium obtained from TM6SF2 E167K spheroids contained lower levels of APOB (Fig. 7A,B). Since there is one APOB protein per secreted VLDL particle28, these data
indicate that hepatocyte spheroids from TM6SF2 E167K carriers secrete fewer APOB VLDL particles compared
to WT spheroids. To further understand whether the reduction in the APOB was due to changes in APOB expression we examined mRNA levels of APOB at day 2 of incubation with FAs in spheroids from both types of donors.
We observed a reduction of mRNA levels in four out of the five donors, where the donors carrying the TM6SF2
E167K protein had a slightly lower reduction (−0.15 fold, TM6SF2 E167K-1 and −0.79 fold, TM6SF2 E167K-2)
SCIENTIFIC REPORTS |
(2019) 9:11585 | https://doi.org/10.1038/s41598-019-47737-w
4
www.nature.com/scientificreports
www.nature.com/scientificreports/
Figure 3. Spheroid viability is not compromised by FA treatment. Total intracellular ATP content measured by
luminescence using CellTiter-Glo 3D Cell Viability Assay (Promega) in primary human hepatocyte spheroids
with and without FA treatment for up to 10 days, using control (FA-free BSA) and two FA concentrations (low
FA, BSA + 107 µM OA/53 µM PA and high FA, BSA + 213 µM OA/107 µM PA). Spheroids were generated from
hepatocytes derived from five individual donors, out of which two were mutant and three were wild type for
TM6SF2 E167K. Data are mean ± SD of eight single spheroid replicates per time point and condition and from
one spheroid preparation per donor. Abbreviations: ATP, adenosine triphosphate; BSA, bovine serum albumin;
FA, fatty acid; OA, oleic acid; PA, palmitic acid.
®
Figure 4. Spheroids are well-differentiated for up to 10 days of fatty acid incubation. Intracelluar (A) and
extracellular (B) APOB protein levels in spheroids and culture medium, respectively, up to 10 days of FA
incubation. APOB was measured by immunoblotting analysis, using anti-APOB and anti-calnexin (CNX)
antibodies, from cell lysate and medium supernatant of primary human hepatocyte spheroids that were derived
from three individual donors. APOB levels were assessed with low (BSA + 107 µM OA/53 µM PA), high
(BSA + 213 µM OA/107 µM PA) and without (FA-free BSA) incubation with FAs. Original, uncropped blots
are presented in Supplementary Fig. S8. This figure shows data from of one independent experiment per donor.
Abbreviations: Ab’, antibody; APOB, APOLIPOPROTEINB100; BSA, bovine serum albumin; CNX, Calnexin;
FA, fatty acid.
SCIENTIFIC REPORTS |
(2019) 9:11585 | https://doi.org/10.1038/s41598-019-47737-w
5
www.nature.com/scientificreports/
www.nature.com/scientificreports
Figure 5. Spheroids accumulate intracellular neutral triglycerides upon incubation with fatty acids. Spheroids
were incubated with a 2:1 mixture of OA and PA (conjugated to BSA), for up to 10 days. Exposure was conducted
using low (BSA + 107 µM OA/53 µM PA) and high (BSA + 213 µM OA/107 µM PA) FA concentration, as well
as FA-free BSA (control). (A) Total TG content of liver spheroids, measured by fluorescence intensity using
AdipoRed Assay Reagent. Spheroids were formed using primary human hepatocytes derived from five
individual donors, out of which two were mutant (TM6SF2 E167K-1, TM6SF2 E167K-2) and three were wild type
(WT-1, WT-2, WT-3) for TM6SF2 E167K. TG content is shown as fold change relative to vehicle control (FA-free
BSA). Data represent mean values ± SD from 16 individual spheroid replicates per time point and condition, from
one spheroid preparation per donor (repeat experiments of the donors TM6SF2 E167K-2, WT-1, and WT-2 are
shown in Supplementary Fig. S7). (B) Nile red staining of low FA and high FA-incubated liver spheroids derived
from three individual hepatocyte donors, after 10 days of FA incubation. Bars = 50 µm. Abbreviations: BSA, bovine
serum albumin; FA, fatty acid; OA, oleic acid; PA, palmitic acid; TG, triglyceride.
™
SCIENTIFIC REPORTS |
(2019) 9:11585 | https://doi.org/10.1038/s41598-019-47737-w
6
www.nature.com/scientificreports/
www.nature.com/scientificreports
Figure 6. Transcriptional data derived from human liver and primary human hepatocyte spheroids show
consistent changes in metabolic pathways when the TM6SF2 E167K variant is carried. Genes related to
cholesterol biosynthesis, de novo lipogenisis and phospholipid dephosphorylation were upregulated both
in human livers and spheroids carrying the rs58542926 risk variant and exposed for 2 days to high FA
concentration (BSA + 213 µM OA/107 µM PA). To be comparable to RNA-Seq analysis, the regulation of key
genes examined in RT-PCR were evaluated relative to FA-treated versus FA-free BSA control samples for both
TM6SF2 E167K and WT. The reported values are the log2 normalized fold changes (log2 FCMUT/FCWT). Error
bars represent the standard error of the mean (SEM) from the two TM6SF2 E167K carriers and the three WTs.
Genes involved in Gluconeogenisis (FBP1), FA β-oxidation (ACADS), and TG metabolism (PNPLA2) where
differentially regulated in humans and spheroids carrying the TM6SF2 E167K risk variant.
than the WT-1 (−1.87 fold) and WT-2 donor (−2.56 fold). APOB expression in WT-3 was unchanged (Fig. 7C).
We also did not observe any difference in APOB expression, nor in the expression of microsomal triglyceride
transfer protein (MTTP), a protein necessary for the assembly of APOB-containing lipoproteins, in the transcriptome of patients at risk for NAFLD carrying the TM6SF2 E167K protein.
Discussion
In this work we show in both human liver tissue samples and in 3D spheroid cultures of primary human hepatocytes that carriage of the TM6SF2 E167K mutant protein is associated with an upregulation of the cholesterol and
FA biosynthesis pathways. We also demonstrate that spheroid cultures with human primary hepatocytes obtained
from two TM6SF2 E167K donors have lower secretion of APOB compared to spheroids formed from hepatocytes
of three wild type (WT) hepatocyte donors investigated.
We started by examining enrichment for significantly differentially expressed genes (by GO and KEGG pathways analyses) in human liver from individuals at risk for liver disease carrying the TM6SF2 E167K sequence variant, as compared to the WT. We found a striking upregulation of most of the enzymes involved in lipid synthesis
and specifically of cholesterol and FA metabolism with both GO and KEGG. Interestingly, KEGG analyses found
an enrichment of genes which are classified as involved in the pathogenesis of viral hepatitis and NAFLD. This is
in line with the human genetic association data showing that TM6SF2 E167K carriers have higher risk not only
for NAFLD but also for progression of liver damage in patients infected by viral hepatitis B and C29,30.
Next, we used a novel 3D spheroid NAFLD model utilizing primary human hepatocytes24 from five individual
donors, two carrying the TM6SF2 E167K protein and three the WT protein. In both TM6SF2 E167K and WT the
ATP levels, as well as APOB synthesis and secretion were preserved up to ten days after formation, indicating that
spheroids were viable, well differentiated and functional within this time frame. Next, to induce intracellular lipid
accumulation, we exposed the spheroids to increasing doses of a mixture of saturated and monounsaturated FAs
for up to 10 days. FA load did not affect spheroid viability and differentiation. Most importantly, in the spheroids
derived from the TM6SF2 E167K donor we consistently found a larger increase in the intracellular fat content
as compared to the WTs, which was dose- and time-dependent. This suggests that the spheroids may represent
a reliable model to study the mechanism underpinning predisposition to lipid accumulation in carriers of the
TM6SF2 E167K variant. Furthermore, the phenotypic expression of the mutation in the presence of excess FAs is
consistent with the recent gene environment interaction observed for this gene variant31.
We examined the intracellular biological pathways by differential expression analysis and found that, consistent with human data, TM6SF2 E167K spheroids had upregulated genes involved in the cholesterol, FA and glucose metabolism. Overall, the directional regulation of genes involved in cholesterol metabolism was consistent
in humans and the spheroid model. We found a discordance in enzymes involved in lipolysis (PNPLA2), gluconeogenesis (FBP1) and β-oxidation (ACADS). While PNPLA2 is a key enzyme in lipolysis, we did not observe
any significant change in the expression of other lipolytic enzymes (LIPE and MGLL) involved in TG hydrolysis
in humans.
SCIENTIFIC REPORTS |
(2019) 9:11585 | https://doi.org/10.1038/s41598-019-47737-w
7
www.nature.com/scientificreports/
www.nature.com/scientificreports
Figure 7. Liver spheroids derived from the TM6SF2 E167K donors show substantially decreased synthesis and
secretion of APOB as compared to spheroids derived from the WT donors. (A) Immunoblots using anti-APOB
and anti-calnexin (CNX) antibodies comparing APOB synthesis (lysate) and secretion (medium) in WT-1,
TM6SF2 E167K-2 and WT-2 show decreased APOB particle number intracellularly and in medium samples
obtained from the TM6SF2 E167K-2 donor after incubation with high FA (BSA + 213 µM OA/107 µM PA)
for up to 10 days. Quantifications relative to WT-1 and WT-2 are shown below the cropped blots. Original,
uncropped blots are provided in Supplementary Fig. S9A. (B) Immunoblot and quantifications layout as
presented in (A), showing donor WT-3 vs. TM6SF2 E167K-1. Original, uncropped Blots are provided in
Supplementary Fig. S9B. (C) Relative mRNA levels of APOB and MTTP (log2 transformed) after a 2-day
incubation with high FA (BSA + 213 µM OA/107 µM PA), normalized to GAPDH and expressed relative to
the levels of FA-free BSA treated control. APOB and MTTP are slightly downregulated in spheroids derived
from the TM6SF2 E167K donors, while the WT-1 and WT-2 donors show a stronger downregulation of
APOB and MTTP. In WT-3, APOB expression was unchanged and MTTP slightly downregulated. The
figure represents data from one experiment per donor and RNA was extracted from 20 pooled spheroids per
donor. Abbreviations: Ab’, antibody; APOB, APOLIPOPROTEINB100; CNX, calnexin; FA, fatty acid; MTTP,
microsomal triglyceride transfer protein; OA, oleic acid; PA, palmitic acid.
Taken all this together, our data indicate that the spheroids generated from TM6SF2 E167K primary hepatocytes have similar metabolic changes present as in livers of human carriers. These changes, namely increased
cholesterol and FA biosynthesis, may contribute to the increase in intracellular fat. Interestingly, excess in free
cholesterol is known to cause hepatic damage32,33. Our data are consistent with increased cholesterol esters in
the liver of TM6SF2 E167K carriers34. Therefore, although we could not evaluate protein expression and directly
measure de novo lipid synthesis, our data suggest that the progression of NAFLD in TM6SF2 E167K carriers could
be ascribed not only to reduced lipid secretion13, but also to the excess synthesis of cholesterol or other lipotoxic
lipid species32,33. Interestingly, the mouse knockout (KO) model and in vitro overexpression of the TM6SF2 E167K
sequence variant accumulates intrahepatic fat, but this was associated with reduced cholesterol biosynthesis17,35,
possibly suggesting that the mouse model may not closely mirror human physiology. However, in contrast to
our results, a previous study reported downregulation of lipid synthesis in the liver of TM6SF2 E167K carriers34.
Next, to investigate on the mechanism of intracellular fat retention we examined the APOB secretion as well
as intracellular synthesis in spheroids. We found that TM6SF2 E167K spheroids show a lower secretion of APOB,
coupled to lower intracellular APOB protein levels. The Tm6sf2 KO mouse was found to have unchanged secretion of APOB particle number17, while a human genetic association study showed lower levels of circulating
APOB15. Our data are consistent with the human genetic association study, indicating a defect in secretion of
APOB particles, which may cause intracellular lipid increase. Regarding the cause of reduction in APOB secretion, we found lower intracellular levels of APOB. This could be due to an increase in APOB degradation, possibly
due to unlipidated or underlipidated forms of APOB36. These data are consistent with the notion that decreased
transfer of FAs on nascent VLDL in the endoplasmic reticulum (lipidation) contributes to intrahepatic fat accumulation in TM6SF2 E167K carriers17. However, differently than in the mice model, we showed that in human
SCIENTIFIC REPORTS |
(2019) 9:11585 | https://doi.org/10.1038/s41598-019-47737-w
8
www.nature.com/scientificreports/
www.nature.com/scientificreports
hepatocytes this defect also results in decreased APOB protein levels and secretion. A limitation of our study is
that we cannot take into account the effect of intestinal uptake of lipids in chylomicrons which is also reduced
in the presence of the TM6SF2 mutant protein in the postprandial state37. However, the data presented in this
study and in previous genetic studies were in a fasting state, minimizing the interference of lipoproteins of the
fed state12,15.
The main limitation of our study is that the number of mutant donors was limited and therefore the results
should be interpreted with caution. In our screening efforts, it was not possible to identify further TM6SF2 E167K
hepatocyte donors because of the relatively low allele frequency of this sequence variant. It should also be taken
into consideration that the two mutant donors were of younger age (13 and 22 years, Supplementary Table S5)
as compared to the three wild type donors (30, 44 and 78 years, Supplementary Table S5), which could influence
hepatocyte function.
In conclusion, we showed a lower APOB secretion in primary human hepatocyte spheroids from TM6SF2
E167K as compared with WT, while the cholesterol biosynthesis was higher in the TM6SF2 E167K spheroids
when exposed to FAs. These data, generated in an experimentally accessible in vitro setting, recapitulate the differences found in human WT and TM6SF2 E167K carriers. Hence, 3D spheroids may represent a useful model to
study mechanism of NAFLD development and impact of genetic background, offering a promising tool for drug
development.
Materials and Methods
Materials. Unless stated otherwise, medium supplements and reagents were obtained from Sigma-Aldrich
(Stockholm, Sweden) and LifeTechnologies (Stockholm, Sweden).
Patient cohort, RNA seq and statistical analyses.
RNASeq was performed in 125 severely obese
individuals who underwent to percutaneous liver biopsy performed during bariatric surgery, as described in
a previous study assessing the role of a genetic variant in the protein phosphatase 1 regulatory subunit 3B gene
(PPP1R3B)38. Informed consent was obtained from each patient and the study protocol was approved by the
Ethical Committee of the Fondazione IRCCS Ca’ Granda, Milan and conformed to the ethical guidelines of the
1975 Declaration of Helsinki. Individuals with increased alcohol intake (men: >30 g/day; women: >20 g/day),
viral and autoimmune hepatitis or other causes of liver disease were excluded. Steatosis was graded based on
the percentage of affected hepatocytes as 0: 0–4%, 1: 5–32%, 2: 33–65%, and 3: 66–100%. NAFLD Activity Score
(NAS) was assessed by systematic evaluation of hepatocellular ballooning and necroinflammation. Fibrosis was
also staged according to the recommendations of the NAFLD clinical research network39.
RNA extraction was performed using miRNeasy mini-kit (Qiagen, Hilden, Germany), according to the manufacturer’s instructions. Agilent 2100 Bioanalyzer was used for RNA qualitative assessment, high-quality samples
(RNA integrity number >7) were used for library preparation. RNA was sequenced in paired-end mode using
an Illumina HiSeq 4000 (Novogene, Hong Kong, China). Reads quality evaluation and trimming was conducted
using FastQC (Babraham Bioinformatics, Cambridge, UK) and Trimmomatic40 packages. Reads were mapped
against GRCh37 reference genome41 using STAR aligner42. Samples with insufficient mapping quality (<10 million mapped reads, uniquely mapped <60% mapped reads) were excluded. Per gene reads were counted according to the ENSEMBL human transcript reference assembly version 75 exploiting RSEM package43. Raw counts
normalization and differential gene expression analysis were performed exploiting DESeq2 package44 according
to the standard workflow. P-values were corrected for testing multiplicity by Benjamini-Hochberg false discovery
rate45.
Gene Ontology (GO) and pathway enrichment analysis. We used GeneTrail2 tool (26787660) to test
for the enrichment of functional annotations among differentially expressed genes between TM6SF2 rs58542926
wild type and E167K mutant carriers (nominal p-value < 0.05). The tests were carried out using Gene Ontology
(GO) Biological Processes (BP) and KEGG pathways. Hypergeometric distribution was used to calculate p-values,
which were subsequently adjusted for multiple hypothesis testing using Benjamini and Hochberg false discovery
rate (FDR) correction45.
3D liver spheroids formation and maintenance.
All cryopreserved primary human hepatocytes used
in this study were obtained from BioIVT (Brussels, Belgium) and thawed according to the supplier’s instructions.
It was not possible to identify additional TM6SF2 E167K donors. The sourcing details and demographics of the
donors are available in Supplementary Table S5. For spheroid formation, the methods described in Bell et al.24 and
Kozyra et al.26 were mainly employed, using slight variations. In short, 2,000 viable cells per well were seeded into
ultra-low adhesion 384-well plates (3830 Corning, Corning, NY, USA) or ultra-low adhesion 96-well plates (7007
Corning, Corning, NY, USA). Total viabilities of the cell preparations after thawing ranged between 90–95%
for hepatocytes from all donors, except for the TM6SF2 E167K-1 donor (84%). Since lower total cell viability is
frequently associated with reduced spheroid formation capability, brief exposure to the pan-caspase apoptosis
inhibitor Z-VAD-FMK was used to support spheroid formation, as described recently46. The same treatment
was done for the WT-3 donor to allow for direct comparisons of both preparations (Fig. 7B). After seeding, the
plates were centrifuged at 100 × g for 2 min. Cells were seeded in Williams E medium (PAN-Biotech, Aidenbach,
Germany), supplemented with 5.5 mM glucose, 2 mM L-glutamine, 100 units/ml penicillin, 100 µg/ml streptomycin, 100 pM insulin, 5.5 µg/ml transferrin, 6.7 ng/ml sodium selenite, 100 nM dexamethasone and 10% fetal
bovine serum. The cells were allowed to aggregate and form spheroids for 7 days, with daily medium change
starting on the fourth day of culture. Medium changes were performed with FBS-free medium of the otherwise
same formulation as described above (maintenance medium). After the start of fatty acid incubation, medium
was changed every 48 hours (Fig. 1).
SCIENTIFIC REPORTS |
(2019) 9:11585 | https://doi.org/10.1038/s41598-019-47737-w
9
www.nature.com/scientificreports
www.nature.com/scientificreports/
Steatosis induction. Hepatic steatosis was induced by metabolic stimulation with the unsaturated FA oleic
acid (OA) and the saturated FA palmitic acid (PA) in a ratio of 2:1, mimicking human plasma concentrations
of free fatty acids (FFAs), as described previously26. Exposure started 7 days after seeding (regarded as day 0, cf.
Fig. 1). FAs were complexed to bovine serum albumin (BSA) for facilitating FFA uptake by the hepatic spheroids.
In short, complexing was achieved by incubating the FAs with 10% BSA (wt/vol, FA-free) in a molar ratio of 1:5
at 40 °C for 2 hours. All complexed solutions were sterile filtered. The OA/PA complex was added to maintenance
medium (described above) for two final total FA concentrations: low, 160 µM (107 µM OA/53 µM PA) and high,
320 µM (213 µM OA/107 µM PA). Controls were supplemented with FA-free BSA in equimolar concentrations as
used in high FA incubation.
Adenosine triphosphate content. Total intracellular adenosine triphosphate (ATP) content was quantified by luminescence using CellTiter-Glo 3D Cell Viability Assay (Promega, Madison, WI, USA) with a slightly
modified protocol. In brief, for each replicate one individual spheroid was transferred by sedimentation into a
white 96-well assay plate (3903 Corning, Corning, NY, USA) containing 50 µl PBS (w/o Mg2+, Ca2+) per well.
Subsequently, 50 µl of assay reagent were added following vigorous mixing for further promoting penetration of
the 3D reagent into the spheroid matrix. The plate was incubated in the dark for 25 min at room temperature and
luminescence was read using a SpectraMax Gemini XS (Molecular Devices, San Jose, CA, USA) reader.
®
Triglyceride imaging.
Intracellular neutral lipid droplets were stained using Nile Red staining, nuclei were
stained using Hoechst 33342 (Invitrogen, Carlsbad, CA). In brief, a double-staining solution containing 2 µM Nile
Red and 16 µM Hoechst 33342 was prepared in PBS (w/o Mg2+, Ca2+). Prior to staining, spheroids were fixed in
a 4% paraformaldehyde solution at room temperature for 1 hour, followed by storage at 4 °C in PBS (w/o Mg2+,
Ca2+). Fixed spheroids were incubated with double-staining solution at room temperature for 90 min, followed
by incubation at 37 °C for 30 min and washing with PBS (w/o Mg2+, Ca2+). Confocal imaging was performed in a
black 96-well assay plate (353219 Corning, Corning, NY, USA) using an LSM880 Airyscan (Zeiss, Jena, Germany)
microscope.
Intracellular triglyceride quantification. Intracellular TG content was determined using a fluorescent
probe that specifically partitions into fat droplets (AdipoRed, Lonza, Switzerland), following the manufacturer’s
instructions with slight modifications. For facilitating access of the reagent to all cells, the spheroids were disintegrated using trypsin treatment. Trypsin solution was prepared by a 1:1 dilution 0.5% trypsin-EDTA with PBS
(w/o Mg2+, Ca2+), of which 200 µl were used per assay in a black 96-well assay plate (3631 Corning, Corning, NY,
USA). For each spheroid replicate (total of 16 per time point), one individual spheroid was taken up in 20 µl of its
maintenance or treatment medium, respectively, and the complete volume transferred into the trypsin solution.
For determining the culture medium-derived background signal, for each replicate (total of eight per time point)
20 µl of maintenance or treatment medium supernatant, respectively, without spheroid were added to the trypsin
solution. The fully prepared assay plate was incubated at 37 °C for 10 min. Following, 7 µl of AdipoRed reagent was
added to each replicate of spheroid sample and culture medium background assay, respectively. For full dissociation of the 3D spheroid cell aggregates, repeated and vigorous resuspending of the suspension was performed.
Subsequently, the assay plate was incubated in the dark at room temperature for 10 min and fluorescence intensity
was measured (ex: 485 nm, em: 572 nm) on an infinite 200 reader (Tecan, Männedorf, Switzerland). The culture
medium-derived signal for each condition was subtracted from all respective spheroid samples prior to determining the relative fold change of fluorescence signal intensity between FA-free BSA control and FA-incubated
conditions.
Intracellular protein isolation.
For protein isolation, spheroids were pooled and washed twice with PBS
(w/o Mg2+, Ca2+). Cell lysis was accomplished by repeated vigorous resuspension of the spheroids at 4 °C in a
mixture of M-PER Mammalian Protein Extraction Reagent (Thermo Scientific, Rockford, IL, USA) and cOmpleteTM Mini Protease Inhibitor (Roche, Mannheim, Germany) working solution (prepared according to the
manufacturer’s instructions), in a ratio of 9:1. The homogenate was sonicated 5 times for 15 s in ice cold water
and subsequently centrifuged at 12000 × g and 4 °C for 15 min. The supernatant was extracted and total protein
concentration determined on a Nanodrop 1000 spectrophotometer (NanoDrop Technologies, Wilmington, DE,
USA). Samples were stored at −80 °C until further analysis.
Immunoblotting for APOB detection.
Cell media samples were concentrated 10 times using Vivaspin
500 columns (Sartorius Stedim Lab Ltd, Stonehouse, UK) for the APOB-100 detection. Cell lysates as well as concentrated and diluted cell media samples were mixed with Laemmli buffer containing 2-mercaptoethanol (ratio
sample: Laemmli buffer = 4:1 v/v) and incubated for 5 min at 95 °C. Proteins were size-separated by SDS-page
(6% acrylamide gel, 90 V, 3 h at 4 °C for APOB-100 and calnexin detection; 10% acrylamide gel, 130 V, 1 h at
room temperature for albumin detection) and transferred onto a nitrocellulose membrane (0.2 A, 2.5 h at 4 °C).
Nitrocellulose membranes were incubated overnight with primary antibodies, washed 3 times for 10 min with
tris-buffered saline containing 0.2% tween (0.2% TBS-T buffer), incubated 1 h with HRP-conjugated secondary antibodies, washed 3 times for 10 min with 0.2% TBS-T buffer, incubated with Immobilon Western chemiluminescent HRP substrate (Millipore Corporation, Billerica, Massachusetts, USA). Bands were visualized
using Chemidoc XRS System (Biorad, Hercules, California, USA). The following antibodies were used: mouse
anti-APOB (Santa Cruz Biotechnology, Dallas, Texas, USA), rabbit anti-calnexin (Sigma-Aldrich, Saint Louis,
Missouri, USA), mouse anti-albumin (Sigma-Aldrich, Saint Louis, Missouri, USA).
Genotyping.
DNA was extracted from hepatocytes using DNeasy Blood & Tissue Kit (Qiagen, Hilden,
Germany). DNA from all donors was undergone to genotyping for TM6SF2_rs58542926 (E167K), PNPLA3
SCIENTIFIC REPORTS |
(2019) 9:11585 | https://doi.org/10.1038/s41598-019-47737-w
10
www.nature.com/scientificreports
www.nature.com/scientificreports/
rs738409 (I148M), PNPLA3 rs2294918 (E434K), GCKR rs1260326 (P446L) and MBOAT7 rs641738 (C > T)
polymorphisms by TaqMan assays (Life Technologies, Carlsbad, CA, USA) using CFX384 Real Time PCR
detection system (Bio-Rad Laboratories, Hercules, CA, USA). Data analysis was performed using Bio-Rad CFX
manager software.
™
Gene expression analysis. Total RNA was isolated using miRNeasy Mini Kit (Qiagen, Hilden, Germany).
RNA was reverse-transcribed into cDNA using High Capacity cDNA Reverse Transcription (Applied Biosystems,
Waltham, MA, USA). RT-qPCR analysis was performed on customized microfluidic TaqMan array 384-well
cards using TaqMan Fast Advanced Master Mix (Applied Biosystems, Waltham, MA, USA) on a QuantStudioTM
7 Flex Real-Time PCR System (Applied Biosystems, Waltham, MA, USA). QuantStudioTM Real-Time PCR
Software, version 1.3, (Applied Biosystems, Waltham, MA, USA) was used for data analysis.
™
™
Data Availability
The datasets generated during and/or analysed during the current study are available from the corresponding
author on reasonable request.
References
1. Loomba, R. & Sanyal, A. J. The global NAFLD epidemic. Nature reviews. Gastroenterology & hepatology 10, 686–690, https://doi.
org/10.1038/nrgastro.2013.171 (2013).
2. Younossi, Z. M. et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and
outcomes. Hepatology 64, 73–84, https://doi.org/10.1002/hep.28431 (2016).
3. Estes, C. et al. Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States
for the period 2016–2030. Journal of Hepatology 69, 896–904, https://doi.org/10.1016/j.jhep.2018.05.036 (2018).
4. Ekstedt, M. et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 44, 865–873, https://doi.
org/10.1002/hep.21327 (2006).
5. Farrell, G. C. & Larter, C. Z. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 43, S99–s112, https://doi.
org/10.1002/hep.20973 (2006).
6. Engin, A. In Obesity and Lipotoxicity (eds Ayse Basak Engin & Atilla Engin) 443–467 (Springer International Publishing, 2017).
7. Francque, S. M., van der Graaff, D. & Kwanten, W. J. Non-alcoholic fatty liver disease and cardiovascular risk: Pathophysiological
mechanisms and implications. J Hepatol 65, 425–443, https://doi.org/10.1016/j.jhep.2016.04.005 (2016).
8. Targher, G., Byrne, C. D., Lonardo, A., Zoppini, G. & Barbui, C. Non-alcoholic fatty liver disease and risk of incident cardiovascular
disease: A meta-analysis. J Hepatol 65, 589–600, https://doi.org/10.1016/j.jhep.2016.05.013 (2016).
9. Eslam, M., Valenti, L. & Romeo, S. Genetics and epigenetics of NAFLD and NASH: Clinical impact. J Hepatol 68, 268–279, https://
doi.org/10.1016/j.jhep.2017.09.003 (2018).
10. Dongiovanni, P. et al. Causal relationship of hepatic fat with liver damage and insulin resistance in nonalcoholic fatty liver. Journal
of internal medicine 283, 356–370, https://doi.org/10.1111/joim.12719 (2018).
11. Kawano, Y. & Cohen, D. E. Mechanisms of hepatic triglyceride accumulation in non-alcoholic fatty liver disease. Journal of
Gastroenterology 48, 434–441, https://doi.org/10.1007/s00535-013-0758-5 (2013).
12. Dongiovanni, P. et al. Transmembrane 6 superfamily member 2 gene variant disentangles nonalcoholic steatohepatitis from
cardiovascular disease. Hepatology 61, 506–514, https://doi.org/10.1002/hep.27490 (2015).
13. Kozlitina, J. et al. Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver
disease. Nat Genet 46, 352–356, https://doi.org/10.1038/ng.2901 (2014).
14. Holmen, O. L. et al. Systematic evaluation of coding variation identifies a candidate causal variant in TM6SF2 influencing total
cholesterol and myocardial infarction risk. Nat Genet 46, 345–351, https://doi.org/10.1038/ng.2926 (2014).
15. Kim, D. S. et al. Novel association of TM6SF2 rs58542926 genotype with increased serum tyrosine levels and decreased apoB-100
particles in Finns. Journal of lipid research 58, 1471–1481, https://doi.org/10.1194/jlr.P076034 (2017).
16. Ehrhardt, N. et al. Hepatic Tm6sf2 overexpression affects cellular ApoB-trafficking, plasma lipid levels, hepatic steatosis and
atherosclerosis. Human molecular genetics 26, 2719–2731, https://doi.org/10.1093/hmg/ddx159 (2017).
17. Smagris, E., Gilyard, S., BasuRay, S., Cohen, J. C. & Hobbs, H. H. Inactivation of Tm6sf2, a Gene Defective in Fatty Liver Disease,
Impairs Lipidation but Not Secretion of Very Low Density Lipoproteins. The Journal of biological chemistry 291, 10659–10676,
https://doi.org/10.1074/jbc.M116.719955 (2016).
18. Lau, J. K. C., Zhang, X. & Yu, J. Animal models of non‐alcoholic fatty liver disease: current perspectives and recent advances. The
Journal of Pathology 241, 36–44, https://doi.org/10.1002/path.4829 (2017).
19. Kanuri, G. & Bergheim, I. (2013).
20. Lin, C., Ballinger, K. R. & Khetani, S. R. The application of engineered liver tissues for novel drug discovery. Expert Opinion on Drug
Discovery 10, 519–540, https://doi.org/10.1517/17460441.2015.1032241 (2015).
21. Hebbard, L. & George, J. Animal models of nonalcoholic fatty liver disease. Nature reviews. Gastroenterology & hepatology 8, 35–44,
https://doi.org/10.1038/nrgastro.2010.191 (2011).
22. McGonigle, P. & Ruggeri, B. Animal models of human disease: challenges in enabling translation. Biochemical pharmacology 87,
162–171, https://doi.org/10.1016/j.bcp.2013.08.006 (2014).
23. Ewart, L. et al. Application of Microphysiological Systems to Enhance Safety Assessment in Drug Discovery. Annual review of
pharmacology and toxicology 58, 65–82, https://doi.org/10.1146/annurev-pharmtox-010617-052722 (2018).
24. Bell, C. C. et al. Characterization of primary human hepatocyte spheroids as a model system for drug-induced liver injury, liver
function and disease. Sci Rep 6, 25187, https://doi.org/10.1038/srep25187 (2016).
25. Messner, S., Agarkova, I., Moritz, W. & Kelm, J. M. Multi-cell type human liver microtissues for hepatotoxicity testing. Arch Toxicol
87, 209–213, https://doi.org/10.1007/s00204-012-0968-2 (2013).
26. Kozyra, M. et al. Human hepatic 3D spheroids as a model for steatosis and insulin resistance. Scientific Reports 8, 14297, https://doi.
org/10.1038/s41598-018-32722-6 (2018).
27. Pingitore, P. & Romeo, S. The role of PNPLA3 in health and disease. Biochimica et biophysica acta, https://doi.org/10.1016/j.
bbalip.2018.06.018 (2018).
28. Walldius, G. & Jungner, I. Rationale for using apolipoprotein B and apolipoprotein A-I as indicators of cardiac risk and as targets for
lipid-lowering therapy. European heart journal 26, 210–212, https://doi.org/10.1093/eurheartj/ehi077 (2005).
29. Eslam, M. et al. Diverse impacts of the rs58542926 E167K variant in TM6SF2 on viral and metabolic liver disease phenotypes.
Hepatology 64, 34–46, https://doi.org/10.1002/hep.28475 (2016).
30. Liu, Z. et al. The effect of the TM6SF2 E167K variant on liver steatosis and fibrosis in patients with chronic hepatitis C: a metaanalysis. Sci Rep 7, 9273, https://doi.org/10.1038/s41598-017-09548-9 (2017).
31. Stender, S. et al. Adiposity amplifies the genetic risk of fatty liver disease conferred by multiple loci. Nat Genet 49, 842–847, https://
doi.org/10.1038/ng.3855 (2017).
SCIENTIFIC REPORTS |
(2019) 9:11585 | https://doi.org/10.1038/s41598-019-47737-w
11
www.nature.com/scientificreports/
www.nature.com/scientificreports
32. Ioannou, G. N. The Role of Cholesterol in the Pathogenesis of NASH. Trends in Endocrinology & Metabolism 27, 84–95, https://doi.
org/10.1016/j.tem.2015.11.008 (2016).
33. Arguello, G., Balboa, E., Arrese, M. & Zanlungo, S. Recent insights on the role of cholesterol in non-alcoholic fatty liver disease.
Biochimica et biophysica acta 1852, 1765–1778, https://doi.org/10.1016/j.bbadis.2015.05.015 (2015).
34. Luukkonen, P. K. et al. Impaired hepatic lipid synthesis from polyunsaturated fatty acids in TM6SF2 E167K variant carriers with
NAFLD. Journal of Hepatology 67, 128–136, https://doi.org/10.1016/j.jhep.2017.02.014 (2017).
35. Fan, Y. et al. Hepatic Transmembrane 6 Superfamily Member 2 Regulates Cholesterol Metabolism in Mice. Gastroenterology 150,
1208–1218, https://doi.org/10.1053/j.gastro.2016.01.005 (2016).
36. Davidson, N. O., Shelness, G. S. & APOLIPOPROTEIN, B. mRNA editing, lipoprotein assembly, and presecretory degradation.
Annual review of nutrition 20, 169–193, https://doi.org/10.1146/annurev.nutr.20.1.169 (2000).
37. O’Hare, E. A. et al. TM6SF2 rs58542926 impacts lipid processing in liver and small intestine. Hepatology 65, 1526–1542, https://doi.
org/10.1002/hep.29021 (2017).
38. Dongiovanni, P. et al. Protein phosphatase 1 regulatory subunit 3B gene variation protects against hepatic fat accumulation and
fibrosis in individuals at high risk of nonalcoholic fatty liver disease. Hepatology Communications 2, 666–675, https://doi.
org/10.1002/hep4.1192 (2018).
39. Kleiner, D. E. et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41,
1313–1321, https://doi.org/10.1002/hep.20701 (2005).
40. Bolger, A. M., Lohse, M. & Usadel, B. Trimmomatic: a flexible trimmer for Illumina sequence data. Bioinformatics (Oxford, England)
30, 2114–2120, https://doi.org/10.1093/bioinformatics/btu170 (2014).
41. Zerbino, D. R. et al. Ensembl 2018. Nucleic acids research 46, D754–d761, https://doi.org/10.1093/nar/gkx1098 (2018).
42. Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics (Oxford, England) 29, 15–21, https://doi.org/10.1093/
bioinformatics/bts635 (2013).
43. Li, B. & Dewey, C. N. RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome. BMC
bioinformatics 12, 323, https://doi.org/10.1186/1471-2105-12-323 (2011).
44. Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome
biology 15, 550, https://doi.org/10.1186/s13059-014-0550-8 (2014).
45. Benjamini, Y. & Hochberg, Y. Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing. Journal
of the Royal Statistical Society. Series B (Methodological) 57, 289–300 (1995).
46. Ölander, M. et al. A simple approach for restoration of differentiation and function in cryopreserved human hepatocytes. Archives
of Toxicology 93, 819–829, https://doi.org/10.1007/s00204-018-2375-9 (2019).
Acknowledgements
Sebastian Prill is a fellow of the AstraZeneca postdoc programme. This work was supported by the Swedish
Research Council [Vetenskapsrådet (VR), 2015-02760 and 2016-01527], the Swedish Heart Lung Foundation
[20120533], the ERC-AdG project HEPASPHER [742020], the Swedish federal government funding under the
Agreement on Medical Training and Medical Research (ALF) [716731], the Novonordisk Foundation Grant for
Excellence in Endocrinology [Excellence Project, 9321-430], the Swedish Diabetes Foundation [DIA 2017-205],
a research grant from AstraZeneca [Echo Project, 10033852], Wallenberg Academy Fellows from the Knut and
Alice Wallenberg Foundation [KAW 2017.0203] (SR), and the Wilhelm and Martina Lundgren Science Fund
[2016-1255] (RMM). AIRC [MFAG N.16888], Italian Ministry of Health [RF-2016-02364358], Fondazione
IRCCS Ca’ Granda - INGM Molecular Medicine Grant.
Author Contributions
S.P. designed and conducted experiments, analyzed and interpreted results, made all figures and drafted portions
of the manuscript. A.C. conducted and analysed western blots, conducted genotyping experiments and reviewed
and interpreted results. O.J. conducted the analysis and integration of transcriptomic data of the human cohort
and 3D spheroids. G.B., P.D., R.R. and A.P. generated and analysed transcriptomic data of human liver samples.
R.M.M. conducted genotyping work. P.P. conducted genotyping and cell experiments and interpreted results.
A.J. conducted experiments and interpreted results, M.K. reviewed and interpreted results. K.K. supervised
experiments and interpreted results. S.R. drafted portions of the manuscript. L.V. and M.I.S. reviewed and
interpreted results and finalised the manuscript. S.R., T.B.A., K.K., C.W. and D.L. developed the study concept,
reviewed and interpreted results and finalised the manuscript.
Additional Information
Supplementary information accompanies this paper at https://doi.org/10.1038/s41598-019-47737-w.
Competing Interests: Sebastian Prill, Kajsa P Kanebratt, Daniel Lindén, Carl Whatling, Annika Janefeldt and
Tommy B Andersson are AstraZeneca employees. Magnus Ingelman-Sundberg is a co-founder of HepaPredict
AB. Stefano Romeo has received consultancy fee and a grant from Astra Zeneca to study fatty liver disease.
Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and
institutional affiliations.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International
License, which permits use, sharing, adaptation, distribution and reproduction in any medium or
format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this
article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the
material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the
copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
© The Author(s) 2019
SCIENTIFIC REPORTS |
(2019) 9:11585 | https://doi.org/10.1038/s41598-019-47737-w
12